Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Solid Tumor × disitamab vedotin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 6 Stomach Neoplasms 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Cancer (MIBC) 1 Head and Neck Neoplasms 1 HER2-low Breast Cancer 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Advanced Breast Cancer 1

Interventions

pembrolizumab 6 Injections 5 tislelizumab 4 senaparib 4 Nivolumab 3 Bevacizumab 3 toripalimab 2 spartalizumab 2 Ipilimumab 2 Fluorodeoxyglucose F18 2 zimberelimab 1 tumor-cells apoptosis factor, human 1 tazemetostat 1 sotorasib 1 sintilimab 1 sacituzumab govitecan 1 rucaparib 1 romiplostim 1 osimertinib 1 olaparib 1 magrolimab 1 enzalutamide 1 cemiplimab 1 cedazuridine 1 binimetinib 1 atezolizumab 1 WW Domain-Containing Oxidoreductase 1 Ultrasonography, Doppler 1 Ultrasonography 1 Technetium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡